Patents by Inventor Narayan Variankaval

Narayan Variankaval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20220062295
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 3, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul A. Harmon, Narayan Variankaval
  • Solid dosage formulations of an orexin receptor antagonist
    Patent number: 11160811
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: November 2, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Paul A. Harmon, Narayan Variankaval
  • SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20190038635
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
    Type: Application
    Filed: August 9, 2018
    Publication date: February 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul A. Harmon, Narayan Variankaval
  • Solid dosage formulations of an orexin receptor antagonist
    Patent number: 10098892
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer. A concentration-enhancing polymer is water soluble or readily disperse in water, so that when the polymer is placed in water or an aqueous environment (e.g. fluids in the gastrointestinal (GI) tract or simulated GI fluids), the solubility and/or bioavailability of suvorexant is increased over the solubility or bioavailability in the absence of the polymer.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: October 16, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Paul A. Harmon, Narayan Variankaval
  • SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20150190402
    Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer. A concentration-enhancing polymer is water soluble or readily disperse in water, so that when the polymer is placed in water or an aqueous environment (e.g. fluids in the gastrointestinal (GI) tract or simulated GI fluids), the solubility and/or bioavailability of suvorexant is increased over the solubility or bioavailability in the absence of the polymer.
    Type: Application
    Filed: May 29, 2013
    Publication date: July 9, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul A. Harmon, Narayan Variankaval
  • ALTERNATIVE FORMS OF THE PHOSPHODIESTERASE-4 INHIBITOR N-CYCLOPROPYL-1--4-OXO-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYAMIDE
    Publication number: 20130231363
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Application
    Filed: March 31, 2010
    Publication date: September 5, 2013
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • Alternative Forms of the Phosphodiesterase-4 Inhibitor N-Cyclopropyl-1--4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
    Publication number: 20110245290
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Application
    Filed: March 31, 2010
    Publication date: October 6, 2011
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • SYNTHESIS AND CRYSTALLINE FORMS OF CB-1 ANTAGONIST/INVERSE AGONIST
    Publication number: 20100292282
    Abstract: The present invention relates to a process for producing crystalline 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methyl-propyl]-5-fluorobenzonitrile, and novel salts, solvates, hydrates and polymorphs thereof.
    Type: Application
    Filed: October 20, 2008
    Publication date: November 18, 2010
    Inventors: Kevin R. Campos, Cheng-Yi Chen, Jennifer R. Foley, Michael Hillier, Wendy S. Jen, Amude M. Kassim, Artis Klapars, Andrey V. Peresypkin, Thorsten Rosner, Cecile G. Savarin, Matthew Tudge, Narayan Variankaval, Vicky Vydra, Dalian Zhao
  • NOVEL INHIBITORS OF BETA-LACTAMASE
    Publication number: 20100009957
    Abstract: A class of 7-oxo-2,6-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are ?-lactamase inhibitors. The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with ?-lactam antibiotics. In particular, the compounds are suitable for use with ?-lactam antibiotics (e.g., imipenem and ceftazidime) against micro-organisms resistant to ?-lactam antibiotics due to the presence of the ?-lactamases.
    Type: Application
    Filed: September 24, 2007
    Publication date: January 14, 2010
    Inventors: Timothy A. Blizzard, Helen Y. Chen, Jane Yang Wu, Seongkon Kim, Sookhee Ha, Christopher J. Mortko, Narayan Variankaval, Anna Chiu
  • Altenrative Forms Of The Phosphodeisterase -4 Inhibitor N-Cyclopropyl-1- -3{3-[(1-Oxidopyryidin-3-Yl) Phenyl]-4-Oxo-1,4-Dihydro-1,8-Naphthyridine-3-Carboxyamide
    Publication number: 20080119509
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below: Compound IX
    Type: Application
    Filed: April 22, 2005
    Publication date: May 22, 2008
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval